Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
We aim to compare the biological staging of Alzheimer Disease using two different tau PET tracers.
Why it matters
This entry only states an aim to compare two tau PET tracers for biological staging of Alzheimer disease. No results are reported, so it provides no information on treating, curing, or preventing the disease.
-
BackgroundIndividuals with Down syndrome (DS) generally show neuropathological features of Alzheimer disease (AD).
Why it matters
In 120 adults, those with Down syndrome had higher superoxide dismutase and catalase activity, while glutathione peroxidase, malondialdehyde and 4-hydroxy-2-nonenal were similar between groups. The authors suggest antioxidant changes may be involved in neurodegeneration, but no treatment, cure or prevention was tested.
-
The first search utilized the following MeSH terms and keywords: ‘Plasma Exchange’, ‘Plasmapheresis’, ‘Therapeutic plasma exchange’, ‘Apheresis’, ‘Aβ’, ‘p-tau’, ‘Total-tau’, ‘Alzheimer's disease’, ‘Cognitive dysfunction’, ‘neurodegenerative diseases’, ‘centrifugation’, ‘membranous’, and ‘filtration’ in the Title/Abstract, yielding 146 results.
Why it matters
This review examines how therapeutic plasma exchange with albumin replacement might remove or bind amyloid-β in Alzheimer's disease, based on searches of the literature on plasma exchange, albumin structure and albumin-Aβ interactions. It presents current insights and future perspectives only; no clinical trial results or evidence of benefit for patients are reported in the text provided.
-
Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and cause of dementia.
Why it matters
This review discusses ROCK inhibition as a possible approach for Alzheimer's disease, based on observations that ROCK1/2 levels are elevated in the disease and that ROCK activity changes synapses, protein aggregates and inflammation. It summarizes findings rather than reporting a proven treatment, cure or prevention.
-
Our findings showed the strong predictive potential of PET, particularly florbetaben (FBB), which achieved an AUC of 0.84.
Why it matters
This study found that PET imaging and neurocognitive tests could distinguish between stable and progressive mild cognitive impairment. It is about improving early diagnosis and does not test any treatment, cure, or prevention.
-
Alzheimer disease (AD) diagnosis is confirmed using a medley of modalities, such as the detection of amyloid-β (Aβ) neuritic plaques and neurofibrillary tangles with positron electron tomography (PET) or the appraisal of irregularities in cognitive function with examinations.
Why it matters
A composite of plasma Aβ40, total tau and Aβ42 correlated better with amyloid imaging and cognitive tests than a simpler tau-to-Aβ42 comparison in a small sample of 53 subjects. This is an early diagnostic finding and does not test any treatment.
-
and neurogranin changes correlated with sabirnetug-AβO target engagement (p ≤ 0.01).
Why it matters
In this phase 1 trial, three doses of sabirnetug were followed by changes in cerebrospinal fluid and plasma biomarkers that increased with dose and exposure duration. The study was small and early, and a larger phase 2 trial is planned to test whether these effects hold up.
-
Physical performance may be a valuable tool in early dementia detection in clinical settings and could identify targets for early intervention.
Why it matters
This study found that physical performance measures such as the Mini Physical Performance Test and balance distinguished mild cognitive impairment from normal cognition and subjective cognitive decline, with Alzheimer's etiology accounting for most group differences. The findings suggest physical performance could serve as an early marker of dementia risk, but no treatment, cure, or prevention was tested.
-
39/100
[18F]GTP1 exhibited retention patterns that correlated with [18F]PI-2620 and [18F]MK-6240 for all Braak regions (except Braak II).
Why it matters
This study found that three different tau PET tracers showed similar uptake patterns in Alzheimer's disease patients, suggesting they detect the same tau pathology. However, each tracer had its own pattern of off-target signal, which may affect how directly they can be compared.
-
On March 12–14, 2024, the National Institute on Aging (NIA) together with the National Institute of Neurological Disorders and Stroke (NINDS) led a workshop exploring clinically meaningful changes in the context of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) clinical trials ( https://www.nia.nih.gov/research/dbsr/workshops/clinically‐meaningful‐outcomes‐ad‐adrd‐trials ).
Why it matters
This report describes a workshop on how to define and measure clinically meaningful change in Alzheimer's and related dementia trials, focused on biomarkers, cognition and everyday function. It offers guidance for trial design and outcome selection rather than findings about treating, curing or preventing the disease.
-
Preliminary analysis indicates significant differences in location, ethnoracial background, ADI, and TRAP exposure amongst UCD ADRC participants.
Why it matters
This abstract describes the launch of a study on traffic-related air pollution and cognition in a diverse Alzheimer's Disease Research Center cohort. It reports on the geographic and demographic makeup of the cohort and does not yet test whether air pollution affects cognition or whether any treatment works.
-
The purpose of this study was to investigate whether plasma biomarkers can help to diagnose, differentiate from Alzheimer disease (AD), and stage cognitive performance in patients with positron emission tomography (PET)-confirmed primary age-related tauopathy, termed tau-first cognitive proteinopathy (TCP) in this study.
Why it matters
This multi-center study examined whether plasma biomarkers can help diagnose and stage patients with PET-confirmed primary age-related tauopathy, compared with young-onset and late-onset Alzheimer's disease and unimpaired controls. It is about diagnosis and staging, not treatment, cure or prevention.
-
Specific health plans for DS and conducting clinical and translational research on the challenges of aging, including AD, are necessary and feasible.
Why it matters
This paper describes a new clinical and research cohort for adults with Down syndrome, in which 114 people joined in the first year and 36% showed symptoms indicative of Alzheimer's disease. It presents a care and research platform and reports no treatment, cure or prevention results.
-
Considerable research has linked many risk factors to Alzheimer's Disease and Related Dementias (ADRD).
Why it matters
This county-level study ranked factors linked to Alzheimer's and related dementias, with insufficient sleep, low fruit and vegetable intake, and not finishing high school ranking highest. It identifies associations to guide further research and does not test any treatment or prevention.
-
As disease-modifying therapies become available for Alzheimer's disease (AD), detection of AD in early stages of illness (mild cognitive impairment [MCI], early dementia) becomes increasingly important.
Why it matters
This secondary analysis of 185 participants in Lima, Peru evaluated whether the memory alteration test detects biomarker-proven Alzheimer's disease and correlates with neurodegeneration and CSF biomarkers. It addresses low-cost detection in places where biomarkers are costly and not widely available, not treatment, cure or prevention.
-
Alzheimer's disease (AD) is one of the pathologies that the scientific world is still desperate for.
Why it matters
This study compared levels of diazepam binding inhibitor and other biomarkers among newly diagnosed Alzheimer's patients, patients diagnosed five years earlier, and healthy controls. It is a biomarker comparison and does not report any treatment, cure, or prevention.
-
The ASURE trial design is discussed, with a particular focus on fluid biomarkers, EEG, and CFC as endpoints.
Why it matters
This is a protocol for a proof-of-concept trial testing an oral edaravone formulation in early Alzheimer's disease patients. No results are included, so it is unknown whether the treatment is safe or effective.
-
Successful back-translating clinical biomarkers and molecular imaging methods of Alzheimer's disease (AD), including positron emission tomography (PET), are very valuable for the evaluation of new therapeutic strategies and increase the quality of preclinical studies. 18 F-Fluorodeoxyglucose (FDG)-PET and 18 F-Florbetaben-PET are clinically established biomarkers capturing two key pathological features of AD.
Why it matters
In 7-month-old female 5XFAD mice, PET imaging showed reduced brain glucose metabolism and increased amyloid deposition compared with wild-type animals, with hypometabolism more pronounced in females. This is animal imaging research and does not test any treatment, cure, or prevention for Alzheimer's disease in people.
-
Alzheimer's Disease (AD) is a neurodegenerative disease that affects cognition and is the most common cause of dementia in the elderly.
Why it matters
This review compares statistical and machine learning approaches used in omics-based studies of Alzheimer's disease. It suggests omics techniques may help identify biomolecular markers and pathways, but it is a review of methods, not a treatment or cure.
-
According to the amyloid, tau, neurodegeneration research framework classification, amyloid and tau positive (A+T+) mild cognitive impairment (MCI) individuals are defined as prodromal Alzheimer disease.
Why it matters
This study compared clinical and biomarker features between people with mild cognitive impairment who progressed to dementia and those who remained stable, to identify predictors of progression within 2 years. It is an observational study and does not test any treatment or cure.
-
The hallmarks of Alzheimer's disease (AD) pathology include senile plaques accumulation and neurofibrillary tangles, which is thought to underlie synaptic failure.
Why it matters
In rats given glutamate injections into the dentate gyrus, memantine inhibited the anxiogenic responses and perturbed spatial memory that glutamate evoked, and memantine also abrogated most of the degenerative changes associated with glutamate. This animal study suggests glutamate excitotoxicity through NMDA receptor hyperactivation is involved in Alzheimer-like pathogenesis, but it does not establish a treatment, cure, or prevention for human Alzheimer's disease.
-
The burden of Alzheimer disease (AD) on the US healthcare system is substantial and increasing.
Why it matters
This review describes Alzheimer's disease as progressing along a continuum from preclinical disease to mild cognitive impairment and then dementia, and states that early diagnosis has benefits for patients and caregivers and appears cost-effective. It notes that currently available biomarkers such as amyloid PET and cerebrospinal fluid tests are expensive.
-
This is a review, not a new study: a panel of scientists and clinicians examined the existing evidence on how sex and gender shape Alzheimer's risk, symptoms, and care.
Why it matters
This review by a panel of scientists and clinicians concluded that sex and gender have been largely ignored in Alzheimer's research and precision-medicine approaches. It is a call for the field to take biological sex and social gender more seriously in research and clinical practice, not a new study result.
-
39/100
Amyloid plaques, along with neurofibrillary tangles, are a neuropathologic hallmark of Alzheimer disease (AD).
Why it matters
This review describes how amyloid PET imaging is used clinically to evaluate suspected neurodegenerative disorders and notes appropriate use criteria for patients with unexplained mild cognitive impairment, uncertain Alzheimer's diagnosis, or atypically early-onset dementia. It states that the overall impact of amyloid imaging is still being evaluated, so it does not establish that imaging improves patient outcomes.
-
Thioflavin T derivatives are used in positron-emission tomography (PET) studies to detect amyloid protein deposits in patients with Alzheimer disease.
Why it matters
This review discusses how amyloid PET tracers, which bind extensively to white matter, may be useful in studies of multiple sclerosis and how proteins from proteolytic processing of the amyloid precursor protein may contribute to that disease. It concerns multiple sclerosis rather than Alzheimer's disease and reports no treatment, cure, or prevention for Alzheimer's disease.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome
- P3‐482: Creation and implementation of the nation's first Alzheimer's disease advantage plan
- Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease
- Longitudinal Analysis of Amyloid PET and Brain MRI for Predicting Conversion from Mild Cognitive Impairment to Alzheimer’s Disease: Findings from the ADNI Cohort
- AT(N) Biomarkers Across Modalities in the Pathways Between Multimorbidity and Cognition
- Genetically decreased vitamin D and risk of Alzheimer disease
- Characteristics of Older Adults with Alzheimer's Disease Who Were Hospitalized during the COVID-19 Pandemic: A Secondary Data Analysis
- Plasma Biomarkers in the Distinction of Alzheimer’s Disease and Frontotemporal Dementia
- Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia
- Machine learning models for dementia screening to classify brain amyloid positivity on positron emission tomography using blood markers and demographic characteristics: a retrospective observational study